Shares of Cerulean Pharma Inc. (NASDAQ:CERU) were down 0.9% during mid-day trading on Monday . The stock traded as low as $2.15 and last traded at $2.23, with a volume of 59,911 shares. The stock had previously closed at $2.25.

Several analysts recently issued reports on CERU shares. Wedbush reissued an “outperform” rating and issued a $9.00 price target on shares of Cerulean Pharma in a report on Tuesday, April 19th. Canaccord Genuity reissued a “buy” rating and issued a $15.00 price target on shares of Cerulean Pharma in a report on Wednesday, April 20th. Janney Montgomery Scott assumed coverage on Cerulean Pharma in a research note on Wednesday, June 1st. They set a “buy” rating on the stock. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Cerulean Pharma in a research note on Sunday, June 26th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Cerulean Pharma presently has an average rating of “Buy” and a consensus target price of $9.28.

The stock’s market cap is $59.52 million. The stock’s 50-day moving average is $2.25 and its 200 day moving average is $2.55.

Cerulean Pharma (NASDAQ:CERU) last announced its quarterly earnings data on Monday, May 2nd. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.06. On average, equities analysts predict that Cerulean Pharma Inc. will post ($1.80) earnings per share for the current year.

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.